Earnings Report | 2026-04-16 | Quality Score: 95/100
Earnings Highlights
EPS Actual
$-0.04
EPS Estimate
$-0.0422
Revenue Actual
$1271789000.0
Revenue Estimate
***
US stock return on invested capital analysis and economic value added calculations to identify truly exceptional businesses with durable competitive advantages. Our quality metrics help you find companies that generate superior returns on capital employed in their business operations. We provide ROIC analysis, economic value added calculations, and capital efficiency metrics for comprehensive quality assessment. Find quality businesses with our comprehensive quality analysis and return metrics for long-term investment success.
Tempus AI Inc. (TEM) has released its latest the previous quarter earnings results, marking the most recently available financial data for the precision medicine AI firm as of this month. The company reported quarterly revenue of approximately $1.27 billion, with an adjusted earnings per share (EPS) of -$0.04 for the quarter. The results cover the final quarter of the company’s prior fiscal year, and reflect both ongoing revenue growth from its core product lines and continued investments in res
Executive Summary
Tempus AI Inc. (TEM) has released its latest the previous quarter earnings results, marking the most recently available financial data for the precision medicine AI firm as of this month. The company reported quarterly revenue of approximately $1.27 billion, with an adjusted earnings per share (EPS) of -$0.04 for the quarter. The results cover the final quarter of the company’s prior fiscal year, and reflect both ongoing revenue growth from its core product lines and continued investments in res
Management Commentary
During the official earnings call, Tempus AI leadership focused on three core highlights from the quarter: expanded adoption of its AI-powered clinical decision support tools across U.S. oncology care networks, a series of new multi-year partnership agreements with top biopharmaceutical clients for clinical trial patient recruitment and real-world evidence generation, and progress in the development of its next-generation generative AI models designed to analyze genomic sequencing data for rare disease diagnosis. Management noted that the quarterly operating expense levels were aligned with previously disclosed investment plans, with a majority of new spending allocated to scaling R&D teams and expanding the company’s de-identified real-world patient data repository, which is a core input for its AI models. Leadership also emphasized that recurring revenue from enterprise biopharma clients grew at a faster rate than one-off service revenue during the quarter, a trend they view as a positive indicator of long-term customer retention.
TEM (Tempus AI Inc.) tops EPS estimates and posts 83 percent year over year revenue growth, shares fall 3.53 percent today.Investors often monitor sector rotations to inform allocation decisions. Understanding which sectors are gaining or losing momentum helps optimize portfolios.Investors may adjust their strategies depending on market cycles. What works in one phase may not work in another.TEM (Tempus AI Inc.) tops EPS estimates and posts 83 percent year over year revenue growth, shares fall 3.53 percent today.Combining technical and fundamental analysis allows for a more holistic view. Market patterns and underlying financials both contribute to informed decisions.
Forward Guidance
Tempus AI did not issue specific numerical forward guidance alongside the the previous quarter earnings release, but outlined key strategic priorities for upcoming operational periods. These priorities include scaling deployment of its latest clinical AI tools to additional hospital systems, expanding commercial operations in select international markets, and continuing to invest in AI model training to improve the accuracy of its diagnostic and treatment recommendation tools. Analyst consensus estimates suggest that the company’s revenue growth may remain steady in upcoming periods, driven by broader industry adoption of AI in healthcare and life sciences workflows. However, market analysts also note that ongoing R&D and market expansion investments could potentially keep operating margins under pressure in the near term, as the company prioritizes market share capture over near-term profitability.
TEM (Tempus AI Inc.) tops EPS estimates and posts 83 percent year over year revenue growth, shares fall 3.53 percent today.The role of analytics has grown alongside technological advancements in trading platforms. Many traders now rely on a mix of quantitative models and real-time indicators to make informed decisions. This hybrid approach balances numerical rigor with practical market intuition.Timing is often a differentiator between successful and unsuccessful investment outcomes. Professionals emphasize precise entry and exit points based on data-driven analysis, risk-adjusted positioning, and alignment with broader economic cycles, rather than relying on intuition alone.TEM (Tempus AI Inc.) tops EPS estimates and posts 83 percent year over year revenue growth, shares fall 3.53 percent today.Real-time data analysis is indispensable in today’s fast-moving markets. Access to live updates on stock indices, futures, and commodity prices enables precise timing for entries and exits. Coupling this with predictive modeling ensures that investment decisions are both responsive and strategically grounded.
Market Reaction
Following the release of the the previous quarter earnings results, TEM traded with near-average volume in subsequent sessions, reflecting mixed investor sentiment around the results. Sell-side analyst notes published after the call indicate that the reported revenue figure was roughly in line with consensus market expectations, while the adjusted EPS figure was slightly ahead of prior analyst estimates. Some market participants have focused positively on the company’s growing recurring revenue share and expanding partnership pipeline, while others have raised questions about the expected timeline for the company to reach positive adjusted operating margins. The broader healthcare AI subsector has seen heightened volatility in recent weeks, which may also be contributing to TEM’s post-earnings price action, as investors re-evaluate growth expectations for AI-enabled enterprise software firms across sectors.
Disclaimer: This analysis is for informational purposes only and does not constitute investment advice.
TEM (Tempus AI Inc.) tops EPS estimates and posts 83 percent year over year revenue growth, shares fall 3.53 percent today.Investors often monitor sector rotations to inform allocation decisions. Understanding which sectors are gaining or losing momentum helps optimize portfolios.Some traders rely on alerts to track key thresholds, allowing them to react promptly without monitoring every minute of the trading day. This approach balances convenience with responsiveness in fast-moving markets.TEM (Tempus AI Inc.) tops EPS estimates and posts 83 percent year over year revenue growth, shares fall 3.53 percent today.Some traders adopt a mix of automated alerts and manual observation. This approach balances efficiency with personal insight.